IE
ARCT icon

Israel Englander’s Arcturus Therapeutics ARCT Stock Holding History

Israel Englander’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$1.84M – 5985
2025
Q3 		$1.84M Buy
+100,000
New +$1.61M ﹤0.01% 4128
2021
Q2 		– Sell
-166,000
Closed -$6.86M – 6495
2021
Q1 		$6.86M Buy
+166,000
New +$9.9M ﹤0.01% 2228

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Israel Englander's ARCT Position: Q2 2026 in Review

Israel Englander reduced its Arcturus Therapeutics (ARCT) stake by 30% in Q2 2026, selling an estimated $1.12M and leaving 336,996 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3722.

Israel Englander first reported a position in ARCT in Q1 2014 and has held it in 28 quarters since. The position peaked at $13.5M in Q2 2024. 133 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Israel Englander held 336,996 shares of Arcturus Therapeutics worth $2.26M as of Q2 2026.
  • Israel Englander sold 141,561 Arcturus Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Arcturus Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3722 holding.
  • Israel Englander first reported a position in Arcturus Therapeutics in Q1 2014 and has held it in 28 quarters since.
  • Israel Englander's Arcturus Therapeutics position peaked at $13.5M in Q2 2024.
  • 133 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.